QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,036 signal articles · 514 in last 24h · 103,484 total before filter · latest 1h ago
514last 24h
2492last 7d
477● bullish (7d)
256● bearish (7d)
197publishers
AllMacro242Earnings1463M&A140Regulatory16Product4Analyst29
✕ clear all filtersticker: GESentiment:bullishneutralbearishshow all (incl. clickbait)
Genie Energy (GNE) Q1 2026 Earnings Transcript
Motley Fool82d agoneutral
Genie Energy (GNE) Q1 2026 Earnings Transcript

Michael Stein: Thank you, operator. GE's first quarter results were mixed as investments in the customer acquisition at GRE and the new business initiatives at GREW, combined with weakness in retail margins negatively impacted our bottom line despite record quarterly revenue. At GRE, challenging commodity market conditions in the first 2 months of the quarter caused by extreme cold compressed margins for both electricity and gas.

GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip
24/7 Wall St.97d agobearish
GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip

GE HealthCare (NASDAQ: GEHC) currently trades at $59.49, well below the Wall Street consensus price target of $89.74. That implies upside of roughly 50.8% if the analysts are right. GE HealthCare is the medical imaging and diagnostics business spun from General Electric, with about $20.6 billion in annual revenue across Advanced Imaging Solutions, Patient Care ... GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip

GE HealthCare Technologies Q1 Earnings Call Highlights
MarketBeat98d agoneutral
GE HealthCare Technologies Q1 Earnings Call Highlights

GE HealthCare Technologies (NASDAQ:GEHC) reported first-quarter 2026 results that management said landed at the high end of expectations on revenue, while profits and cash flow guidance for the full year were reduced to reflect higher input costs and a first-quarter supplier-related recall in Pharma